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Abstract
Background: Conjugated linoleic acids (CLA) are in focus of dairy cattle research because of its milk fat reducing
effects. Little is known about the impact of CLA on immune function in dairy cows. Therefore, in the present study
we investigated the effects of a long term supplementation of dairy cows with CLA on the fatty acid profile of
peripheral blood mononuclear cells (PBMC) and their proliferation ex vivo.
Results: The supplementation of dairy cows with either 100 g/d of a control fat preparation (CON, n = 15), 50 g/d
of the control fat preparation and 50 g/d CLA supplement – containing 12.0% cis-9, trans-11 and 11.9% trans-10,
cis-12 CLA of total fatty acid methyl esters – (CLA-50, n = 15) or 100 g/d of the CLA supplement (CLA-100, n = 16)
did not influence the major fatty acids (C18:0, C16:0, cis-9 C18:1, cis-9, cis-12 C18:2, cis-5, cis-8, cis-11, cis-14 C20:4) in
the lipid fraction of PBMC. The proportion of trans-10, cis-12 CLA of total fatty acids was increased in both CLA
supplemented groups, but there was no effect on the cis-9, trans-11 isomer. Furthermore, the proportion of trans-
9 C18:1 and cis-12 C24:1 was reduced in the CLA-100 group. The mitogen stimulated cell proliferation was not
influenced by CLA feeding.
Conclusion: CLA supplementation influenced the FA profile of some minor FA in PBMC, but these changes did not
lead to differences in the mitogen induced activation of the cells.
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Background
Conjugated linoleic acids (CLA) are a group of pos-
itional isomers of linoleic acid, which are characterized
by conjugated double bonds. They are intermediate pro-
ducts in the biohydrogenation of unsaturated fatty acids
(FA) by microorganisms in the rumen [1]. Additionally,
it is reported, that CLA originate from endogenous syn-
thesis in tissues like the mammary gland of ruminants
[2]. Several positive physiological effects are reported for
CLA, like anticarcinogenic (e.g. reviewed by [3,4]), anti-
atherogenic [5] and immunomodulatory [6] properties.
In general, dietary FA are able to influence the function
of immune cells due to different mechanisms, which in-
clude alteration of the membrane, changes in signal
transduction pathways and in lipid mediators like Pros-
taglandin E2 [7]. CLA supplementation e.g. led to
decreased lymphocyte activation of healthy men [8] and
declined proliferative response in rat splenocytes [9].
Dietary CLA are capable to change the FA profile of
human peripheral blood mononuclear cells (PBMC), but
did not alter their function, like the mitogen stimulated
production of PGE2, leukotriene B4 (LTB4), interleukin
(IL)-1β, IL-2 and tumor necrosis factor α (TNF-α) [10].
Although CLA originally occur in dairy cattle, the sup-
plementation of the cows` diet with CLA gains in im-
portance, because it reduces the milk fat content, which
is ascribed to the trans-10, cis-12 isomer [11]. The im-
pact of a CLA supplementation on the immune system
of dairy cows has been rarely investigated. There was no
effect of CLA supplementation on the stimulation index
(SI) of PBMC obtained from primiparous lactating cows
ex vivo 42 and 105 days post partum (pp). But the SI of
splenocytes from the same animals were decreased
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following CLA supplementation [12]. It is unknown, if
the effects are similar in pluriparous cows and over a
longer supplementation period and if the supplementa-
tion changes the FA profile of immune cells, which
might have further downstream effects. Therefore, in the
present investigation the effects of a long term CLA sup-
plementation were evaluated. In the study primiparous
and pluriparous cows were involved. Effects on immune
cells were evaluated by cell proliferation assays using
PBMC and furthermore, the FA profile of PBMC was
analyzed.
Results
Data concerning performance of the cows in the present
study are reported by Pappritz et al. [13].
Fatty acid profile of PBMC
The main FA occurring in PBMC were C18:0 (stearic
acid), C16:0 (palmitic acid), cis-9 C18:1 (oleic acid), cis-9,
cis-12 C18:2 (linoleic acid) and cis-5, cis-8, cis-11, cis-
14 C20:4 (arachidonic acid) (Table 1). CLA supplemen-
tation did not change the proportions of these FA sig-
nificantly, but there was a tendency of increasing C16:0
when CLA was supplemented. Furthermore the propor-
tion of saturated, monounsaturated and polyunsaturated
FA as well as the sum of n-3 and n-6 FA were not influ-
enced by CLA supplementation. Regarding CLA, no
trans-10, cis-12 was found in PBMC of control animals,
but the isomer significantly increased in both supple-
mented groups (Table 1). The effect was not seen for the
other main supplemented isomer cis-9,trans-11, where
no differences were observed between the 3 groups.
Other CLA were significantly more frequently found in
CON and CLA-50 group than in CLA-100 group. When
all CLA isomers are considered together there were no
differences among the groups. Furthermore, CLA sup-
plementation did influence the proportion of trans-
9 C18:1 and cis-15 C24:1 (Table 1). Both FA were signifi-
cantly reduced in CLA-100 group compared to CON.
Ex vivo cell proliferation assay
Cell viability and mitogen stimulated proliferation of
PBMC was evaluated 7, 21, 35, 49, 105 and 182 days pp
by Alamar blue (AB) and MTT assay.
There was no effect of supplementation (p = 0.742 in
MTT assay, p = 0.955 in AB assay) and lactation number
(p = 0.487 in MTT assay and p = 0.972 in AB assay) on
the stimulation index (SI) of PBMC. Furthermore, no
interactions between day of lactation and lactation num-
ber (p = 0.948 in MTT assay and p = 0.861 in AB assay),
supplementation and lactation number (p = 0.702 in
MTT assay and p = 0.792 in AB assay) as well as supple-
mentation and day of lactation (p = 0.821 in MTT assay
and p = 0.128 in AB assay) were found. Only the day of
lactation had a significant effect (p< 0.001 in both
assays, Figure 1). At d 49 pp the SI reached the mini-
mum in both assays. In the AB assay the SI was rising
from d 7 to d 35 pp and in contrast the SI decreased
from d 7 pp until d 49 pp in the MTT assay.
The SI 105 d pp was not correlated with the propor-
tion of cis-9, trans-11 CLA, trans-10, cis-12 CLA, other
CLA isomers or the sum of all CLA isomers in both
assays.
Discussion
The FA profile of immune cells is influenced by FA in
the diet, thus it is possible to modify the FA profile of
these cells by altering the consumption of certain FA [7].
This effect is described for n-3 polyunsaturated FA
(PUFA) from fish oil or preparations of eicosapentaenoic
acid or docosahexaenoic acid [14-16], but also for CLA
[10] in humans. The altered FA profile of the total lipids
and phospholipids, respectively, might cause changes in
the function of the cells, indicated by effecting signaling
pathways or the pattern of lipid mediator production [7].
Most studies were performed with humans, but also
effects of certain FA on immune cell functions in dairy
cows have been reported [17,18]. In these studies the
effects on FA profile of bovine immune cells were not
investigated [19].
In the present study the proportion of CLA in the lipid
fraction of PBMC was low (less than 1% of all fatty acid
methyl esters [FAME]). Due to CLA supplementation
the proportion of trans-10, cis-12 CLA was increased,
but the cis-9, trans-11 isomer remained unchanged. The
trans-10, cis-12 isomer was not found in PBMC of the
control group and it accounted for only 0.004% of total
FAME in the milk fat of the same animals [13]. The cis-
9, trans-11 isomer is the major CLA isomer occurring in
dairy products. It is formed in the rumen by microbial
fermentation [1] and by endogenous synthesis via Δ9-
desaturase in the mammary gland [2]. These sources
might have a greater impact on the proportion of cis-9,
trans-11 CLA in bovine PBMC than the supplementa-
tion. There was also no effect of the diet on the percent-
age of cis-9, trans-11 in the milk fat of the same animals
[13]. In humans, the proportion of CLA in PBMC was
increased after 63 d CLA supplementation (3.9 g/d of
CLA isomers). The cis-9, trans-11 isomer increased from
0.05 to 0.16% of all analyzed FA, which is in the same
range as the proportion in bovine PBMC in the present
study. The trans-10, cis-12 isomer increased from 0.04%
to 0.19% [10], which is much higher than in the present
study. In humans, the main source of CLA is the con-
sumption of dairy products and ruminant meat [20], but
the endogenous synthesis via Δ9-desaturase is also
observed in humans, whereby trans-11 C18:1 serves as a
precursor [21,22].
Renner et al. Lipids in Health and Disease 2012, 11:63 Page 2 of 7
http://www.lipidworld.com/content/11/1/63
The two predominant FA in the lipid fraction of
PBMC were C18:0 and C16:0 in the present study. That
is in line with results from Contreras et al. [19] who
investigated the FA composition of the phospholipid
fraction of PBMC in dairy cows around parturition. In
the present study, the major FA of the lipid fraction of
PBMC were not significantly affected by CLA supple-
mentation, but there was a trend of increased C16:0
following CLA supplementation. The increased percent-
age of C16:0 was also found in the FA profile of ery-
throcytes from new born calves whose mothers
received the CLA supplement during a certain time of
pregnancy [23]. Reasons for this effect are not clarified
yet. CLA, particularly the trans-10, cis-12 isomer, down
regulate the expression of Δ9-desaturase [24,25] and in-
hibit its activity [26] in different tissues. Therefore, a
slight inhibition of Δ9-desaturase might be accountable
for the increased proportion of C16:0. Two minor FA
(<1% of total FAME), trans-9 C18:1 (elaidic acid) and
cis-15 C24:1 (nervonic acid), were affected by CLA sup-
plementation. Their percentage was decreased in CLA-
100 group. Nervonic acid is an important FA in myelin
sphingolipids [27] and therefore in the nervous system.
Elaidic acid is, like other trans C:18:1 FA, mainly found
in partially hydrogenated vegetable oils, but also in fat
of dairy products [28]. In splenocytes obtained from
rats, elaidic acid was only found in phosphatidylethano-
lamine and phosphatidylcholine, when elaidic acid was
supplemented. In this study the elaidic acid supplemen-
tation caused increased mitogen stimulated production
of interleukin-6 [29].
The mitogen stimulated proliferation was investigated
to obtain information about the functionality of PBMC.
The function of the cells was not influenced by the CLA
Table 1 Fatty acid profile of peripheral blood mononuclear cells
Fatty acid Group Probability
CON CLA-50 CLA-100
C16:0 15.30 ± 0.58 16.29 ± 0.41 17.12 ± 0.57 0.061
C18:0 26.81 ± 1.02 27.53 ± 0.82 28.18 ± 0.75 0.532
C18:1c9 13.52 ± 0.51 12.94 ± 0.54 12.46 ± 0.46 0.333
C18:1c11 2.41 ± 0.13 2.25 ± 0.11 2.19 ± 0.08 0.338
C18:1 t9 0.27 ± 0.01a 0.23 ± 0.01ab 0.22 ± 0.01b 0.017
C18:2c9,c12 10.13 ± 0.23 11.07 ± 0.35 10.36 ± 0.27 0.072
CLA-c9,t11 0.17 ± 0.01 0.16 ± 0.01 0.15 ± 0.01 0.071
CLA-t10,c12 0.00 ± 0.00a 0.01 ± 0.00b 0.02 ± 0.00b <0.001
other CLA 0.07 ± 0.01a 0.06 ± 0.01a 0.03 ± 0.01b 0.006
C20:3n-6 3.06 ± 0.14 3.07 ± 0.13 2.95 ± 0.16 0.805
C20:4n-6 11.12 ± 0.42 9.92 ± 0.49 9.96 ± 0.65 0.214
C20:5n-3 1.03 ± 0.08 0.96 ± 0.06 0.94 ± 0.05 0.553
C22:4n-6 1.35 ± 0.07 1.29 ± 0.08 1.27 ± 0.10 0.791
C22:5n-3 4.11 ± 0.29 4.03 ± 0.44 4.05 ± 0.22 0.295
C24:1 c15 0.03 ± 0.01a 0.02 ± 0.01ab 0.01 ± 0.00b 0.03
Minor FA† 11.94 ± 0.61 11.39 ± 0.42 11.27 ± 0.30 0.547
SFA 46.39 ± 1.48 48.09 ± 1.22 49.73 ± 1.28 0.214
MUFA 20.80 ± 0.691 19.78 ± 0.73 18.95 ± 0.48 0.131
PUFA{ 32.81 ± 1.00 32.12 ± 0.90 31.32 ± 1.09 0.576
all C18:1 trans-FA 2.53 ± 0.11 2.34 ± 0.13 2.28 ± 0.13 0.346
all CLA 0.24 ± 0.01 0.23 ± 0.02 0.20 ± 0.01 0.071
all n-3 FA 6.37 ± 0.41 6.01 ± 0.42 6.10 ± 0.24 0.772
all n-6 FA 26.30 ± 0.71 25.98 ± 0.81 25.12 ± 1.00 0.602
n-3/n-6 0.24 ± 0.01 0.24 ± 0.02 0.25 ± 0.02 0.872
MC-FA (C10>C14) 0.53 ± 0.07 0.68 ± 0.10 0.87 ± 0.17 0.176
Fatty acid profile of peripheral blood mononuclear cells from cows that received a control fat preparation (CON, n = 15) or 50 g/d (CLA-50, n = 15) and 100 g/d
(CLA-100, n = 16) of a CLA supplement. Blood samples were taken after 70 and 140 days of supplementation and samples were pooled for each cow. Results are
expressed as % of total fatty acid methyl esters, means ± standard error. p< 0.1 in italics and indicate tendencies. p <0.05 in bold and indicate significant
differences, ab: different letters within a row indicate significant differences, p< 0.05, Tukey test.
† Minor FA contain fatty acids which concentration is less than 1 % of all fatty acids except CLA.
{ includes CLA.
c = cis, t = trans, SFA = saturated fatty acids, MUFA=monounsaturated fatty acids, PUFA=polyunsaturated fatty acids, MC-FA =medium chain fatty acid.
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supplementation, although the fatty acid composition
was slightly altered in the present study. Also the milk
fat depression was observed in the present study. The
milk fat content was reduced dose dependently by 7%
and 12% in CLA-50 and CLA-100 group, respectively, in
the time period from 49 to 182 d pp [13]. Changes in
the SI were observed over the lactation period. It is
known that the immune system of dairy cattle is sup-
pressed after calving [30], which was e. g. demonstrated
by a decreased SI of ConA stimulated PBMC ex vivo
[12]. As a reason for the immunosuppression in the pp
period increased non esterified fatty acids (NEFA) con-
centrations, which result from increasing fat
mobilization, are discussed. NEFA inhibit proliferation
of bovine PBMC in vitro [31]. The immunosuppressive
effect in the pp period was not observed in the MTT
assay of the present study, although NEFA concentra-
tions in plasma were much higher from 7 to 49 d pp
(0.70, 0.66 and 0.69 mmol/L in CON, CLA-50 and CLA-
100 group, respectively) than between d 49 and 182 pp
(0.29, 0.25, 0.22 mmol/L in CON, CLA-50 and CLA-100
group, respectively) [13]. In the AB assay the SI
increased from d 7 to 35 pp, but reached the minimum
at d 49 pp like in the MTT assay. At that time point the
cows of the CLA fed groups turned from negative to
positive calculated energy balance. Until 49 d pp the
cows of the CON group were not in negative calculated en-
ergy balance (14.9±5.4 MJ/d), whereas the calculated energy
balance of the CLA fed cows was negative during that
period (CLA-50 -12.3±5.4 MJ/d and CLA-100 -8.3±5.2 MJ/
d). These differences are based on a lower dry matter (DM)
intake in CLA supplemented groups during the first weeks
of lactation (CON 21.1±0.7 kg/d, CLA-50 18.5±0.7 kg/d
and CLA-100 17.8±0.7 kg/d). In the following period (until
the end of the supplementation 182 d pp), no differences
between the feeding groups occurred in DM intake
(CON 21.6±0.6 kg/d, CLA-50 22.4±0.6 kg/d and
CLA-100 21.2±0.6 kg/) and energy balance (CON
15.3±2.7 MJ/d, CLA-50 10.4±2.6 MJ/d and CLA-100
10.8±2.5 MJ/d) [13]. The differences between AB
and MTT assay might be due to different enzyme
systems involved in reduction of the respective dye.
MTT is mainly reduced by mitochondrial and micro-
somal enzymes and AB by mitochondrial and cyto-
solic enzymes [32].
Hussen et al. [33] examined the leukocyte profile of
PBMC of the present investigation due to CLA supple-
mentation. Although the SI of PBMC was not influenced
by CLA supplementation, there were effects on their
composition. The percentage of CD4+ cells was
decreased from 21 d pp onwards in the CLA-100 group
compared to control and CLA-50 group and CD8+ cells
were slightly increased, starting 21 d pp. The percentage
of monocytes, B-cells and γδ-T cells was not altered by
the diet. Furthermore, IgG1 and IgG2 levels in serum
were significantly lower in the CLA-100 group through-
out the supplementation period.
It is interesting to note that PBMC of calves (5 calves
per group) of the CLA fed cows investigated in the
present experiment showed an effect of the diet in the
MTT assay (SI in CON 3.6±1.0, CLA-50 1.6±0.7, CLA-
100 4.3±0.8), but not in the AB assay on mitogenic re-
sponse immediately after partus and 1 day post natum.
However, at this time, when CLA supplementation was
no longer fed, the cows still did not exhibit differences
in the mitogen stimulated response of PBMC, but the SI
was increasing from d 0 to d 21 pp in all groups [23].
In most studies investigating the effect of CLA on im-
mune function, the FA profiles of the investigated cells
were not analyzed. Altogether, the effects of CLA sup-
plementation to dairy cows are low and effects seen in
other species, e.g. [34,35], could not be observed.
Conclusions
Long term CLA supplementation to dairy cows did not
alter the mitogen-induced proliferation of PBMC
ex vivo, although the trans-10,cis-12 CLA isomer was
increased in the lipid fraction of PBMC. Further
Figure 1 Stimulation index of peripheral blood mononuclear
cells in MTT (A) and Alamar blue assay (B). Cows were
supplemented with a control fat preparation (CON, n = 15) or
50 g/d of a CLA supplement (CLA-50, n = 15) or 100 g/d of a CLA
supplement (CLA-100, n = 16), abc: indicates significant differences
between sampling days, p< 0.05.
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investigations are necessary to evaluate if the increased
proportion of trans-10 cis-12 CLA in the lipid fraction




The experiment was carried out at the experimental sta-
tion of the Friedrich-Loeffler-Institute (FLI) in Braun-
schweig, Germany. The study was conducted according
to the European Community regulations concerning the
protection of experimental animals and the guidelines of
the LAVES (Lower Saxony State Office for Consumer
Protection and Food Safety, Oldenburg, Germany, File
number 33.14.42502-04-071/07). In the study 46 cows,
32 pluriparous and 14 primiparous, were assigned to 3
feeding groups. The control group (CON, n = 15, out of
them 5 primiparous cows) received 100 g/d of a control
fat preparation, the CLA-50 group (n = 15, out of them 4
primiparous cows) received 50 g/d of the control fat
preparation and the CLA supplement, respectively, and
the CLA-100 group (n = 16, out of them 5 primiparous
cows) received 100 g/d of the CLA supplement. The
supplementation period began one day pp and lasted for
182 days. During that time the cows were fed a partial
mixed ration (PMR) containing 37% concentrate and
63% silage (60% maize silage, 40% grass silage based on
DM content) for ad libitum consumption by a compu-
terized feeding station (Type RIC, Insentec, B.V., Mar-
knesse, The Netherlands). The control fat preparation
(SilafatW, BASF SE, Ludwigshafen, Germany) and the
CLA supplement (LutrellW pure, BASF SE, Ludwigs-
hafen, Germany) were given with 4 kg additional con-
centrate, also via a computerized concentrate feeding
station. The CLA supplement contained mainly the cis-
9,trans-11 and the trans-10, cis-12 isomer (12.0% and
11.9% of FAME, respectively).The daily consumption of
each isomer was 4 g/d in the CLA-50 group and 8 g/d
in the CLA-100 group. In the control fat preparation
CLA was substituted by stearic acid, which is also the
main FA in the CLA supplement. Water was offered for
ad libitum consumption. More detailed information
about the animal experiment, including the FA profile of
the supplements, is reported elsewhere [13].
Sample preparation
At day 7, 21, 35, 49, 70, 105, 140 and 182 pp blood
(30 mL) was taken by jugular venipuncture into hepari-
nized vacutainer tubes. PBMC were isolated from
whole-blood by density gradient centrifugation using
Biocoll (Biochrom AG, Berlin, Germany, L 6115). The
samples were processed as described by Renner et al.
[36]. Samples of day 7, 21, 35, 49, 105 and 182 pp were
used to perform cell proliferation assays. The other 2
samples (70 and 140 d pp) were pooled for each cow
and the FA profile of PBMC was analyzed. All samples
were frozen and stored at −80°C in freezing medium
containing fetal bovine serum (FBS, Biochrom AG,
Berlin, Germany, S 0615) and 10% dimethyl sulfoxide
(DMSO, Sigma-Aldrich, Steinheim, Germany, D 2438).
Analysis of fatty acid profile
The PBMC were washed 3 times with saline to remove
freezing medium. Cellular lipids were extracted accord-
ing to the procedure described by Bligh and Dyer [37]
using a methanol/chloroform mixture. The extracted
lipids were then transesterificated with Boron trifluoride
(BF3) to produce FAME, followed by a purification of
the extracts using thin-layer chromatography (SIL G-25
UV254, Macherey-Nagel, Dueren, Germany). FAME were
analyzed by gas chromatography ([GC], GC-17A Version
3, Schimadzu, Kyoto, Japan), fitted with an auto sampler
and flame ionization detector. Two different procedures
were necessary to identify all FAME and were conducted
according to Degen et al. [38]. The general FA profile
(FA, whose carbon length is 4 to 25) was analyzed using
a medium polarity column (DB-225 ms, 60 m ×
0.25 mm inner diameter; 0.25 μm film thickness; Agilent
Technologies, Santa Clara, USA). Furthermore, the cis
and trans isomers of C18:1 were separated via a high po-
larity column (SelectTM FAME, 200 m x 0.25 mm inner
diameter, 0.25 μm film thickness; Agilent Technologies,
Santa Clara, USA). The following reference standards
were used as FAME mix to identify FA peaks: No. 463,
674, (Nu-Chek Prep, Inc., Elysian, USA), BR2, BR4, ME
93 (Larodan; Malmö, Sweden), SupelcoW 37 Component
FAME Mix, PUFA No. 3, conjugated linoleic acid, lino-
leic-, linolenic- and octadecenoic acid methyl ester mix
(Supelco; Bellefonte, USA). Results are expressed as per-
centage of total FAME.
Cell proliferation assays
PBMC viability and concanavalin A (ConA, Sigma–
Aldrich, Steinheim, Germany, C 5275) stimulated
proliferation were analyzed by MTT (3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyl-tetrazolium bromide) and Alamar
blue (AB) assay. The procedures were carried out as
described in detail elsewhere [12].
Calculations and statistics
Statistical analyses of the FA profile were performed by a
one factorial analysis of variance (ANOVA) using the
Statistica 8 for the Windows operating system, followed
by a Tukey test. Probabilities below 0.05 were considered
as statistically significant and p< 0.1 as a tendency.
The stimulation index (SI) was calculated by the fol-
lowing equation for the MTT assay:
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SI = optical density (OD) of ConA stimulated PBMC/
OD of non-stimulated PBMC
In the AB assay fluorescence instead of OD was used.
The PROC MIXED procedure with a compound sym-
metry covariance structure and supplementation, day of
lactation and lactation number (primiparous vs pluripar-
ous) as fixed factors as well as interactions of these fac-
tors was performed for statistical analyses of the SI using
SAS (Software package, Version 9.1, SAS Institute, Cary,
NC, USA). Because of frequent measurements during
the experiment and the resulting individual cow effects,
they were considered by the repeated procedure.
Correlations between the proportion of CLA isomers
and the SI at 105 d pp were calculated using Statistica 8.
Abbreviations
AB: Alamar blue; ANOVA: analysis of variance; CLA: conjugated linoleic acid;
CON: control group; ConA: concanavalin A; DM: dry matter; FA: fatty acid;
NEFA: non esterified fatty acids; OD: optical density; PBMC: peripheral blood
mononuclear cells; PUFA: polyunsaturated fatty acids; pp: post partum;
SI: stimulation index.
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